GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Selling, General, & Admin. Expense

Cardiol Therapeutics (TSX:CRDL) Selling, General, & Admin. Expense : C$16.99 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cardiol Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2024 was C$5.08 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was C$16.99 Mil.


Cardiol Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Cardiol Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Selling, General, & Admin. Expense Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 10.45 10.09 27.87 22.37 15.56

Cardiol Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 2.84 5.08 3.99 5.08

Competitive Comparison of Cardiol Therapeutics's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiol Therapeutics's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's Selling, General, & Admin. Expense falls into.



Cardiol Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$16.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiol Therapeutics  (TSX:CRDL) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Cardiol Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiol Therapeutics (TSX:CRDL) Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Executives
Guillermo Torre Senior Officer

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 05-24-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 07-03-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired 02-20-2019

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-23-2022